T细胞淋巴瘤-话题@MedSci

#T细胞淋巴瘤#

96篇内容 | 4879人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1372687, encodeId=b93a13e268776, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Front Oncol：西达本胺（chidamide）治疗中国复发或难治性(R/R) 外周T细胞淋巴瘤（PTCL）的真实世界的疗效, objectType=article, longId=219960, objectId=f2d521996079, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2d521996079, replyNumber=0, likeNumber=100, createdTime=2021-11-09, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2d521996079, moduleTitle=Front Oncol：西达本胺（chidamide）治疗中国复发或难治性(R/R) 外周T细胞淋巴瘤（PTCL）的真实世界的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2d521996079)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372686, encodeId=f27713e26868d, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Blood：结外自然杀伤/T细胞淋巴瘤的新预后预测评分系统！, objectType=article, longId=216362, objectId=99a32163627b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99a32163627b, replyNumber=0, likeNumber=105, createdTime=2021-08-28, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99a32163627b, moduleTitle=Blood：结外自然杀伤/T细胞淋巴瘤的新预后预测评分系统！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99a32163627b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372685, encodeId=e74613e268512, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=科普贴：外周T细胞淋巴瘤（PTCL）, objectType=article, longId=215397, objectId=3c8321539ee2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c8321539ee2, replyNumber=0, likeNumber=132, createdTime=2021-08-08, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c8321539ee2, moduleTitle=科普贴：外周T细胞淋巴瘤（PTCL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c8321539ee2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372684, encodeId=aefb13e2684fc, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Blood：血管免疫母细胞性T细胞淋巴瘤的预后和预后因素, objectType=article, longId=215164, objectId=2d38215164c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d38215164c7, replyNumber=0, likeNumber=128, createdTime=2021-08-03, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d38215164c7, moduleTitle=Blood：血管免疫母细胞性T细胞淋巴瘤的预后和预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d38215164c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372683, encodeId=08e913e268390, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性, objectType=article, longId=214110, objectId=d47e2141105c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d47e2141105c, replyNumber=0, likeNumber=90, createdTime=2021-07-14, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d47e2141105c, moduleTitle=J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d47e2141105c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372682, encodeId=c3d913e268272, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=协和麒麟mogamulizumab单抗在中国递交上市申请，用于皮肤T细胞淋巴瘤, objectType=article, longId=213745, objectId=e743213e45ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e743213e45ef, replyNumber=0, likeNumber=107, createdTime=2021-07-06, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e743213e45ef, moduleTitle=协和麒麟mogamulizumab单抗在中国递交上市申请，用于皮肤T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e743213e45ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372681, encodeId=587c13e268176, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Solasia宣布在日本提交抗癌药物DARINAPARSIN用于外周T细胞淋巴瘤的新药申请, objectType=article, longId=213648, objectId=33d021364893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33d021364893, replyNumber=0, likeNumber=129, createdTime=2021-07-04, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33d021364893, moduleTitle=Solasia宣布在日本提交抗癌药物DARINAPARSIN用于外周T细胞淋巴瘤的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33d021364893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372680, encodeId=965813e268000, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=2020 CCO | 张清媛教授：外周T细胞淋巴瘤的治疗进展, objectType=article, longId=203797, objectId=5552203e971c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5552203e971c, replyNumber=0, likeNumber=154, createdTime=2020-11-28, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5552203e971c, moduleTitle=2020 CCO | 张清媛教授：外周T细胞淋巴瘤的治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5552203e971c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372679, encodeId=170313e26798d, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Blood：组蛋白脱乙酰基酶和DNA甲基转移酶双重抑制可有效治疗外周T细胞淋巴瘤, objectType=article, longId=203701, objectId=4e38203e015a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e38203e015a, replyNumber=0, likeNumber=89, createdTime=2020-11-26, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e38203e015a, moduleTitle=Blood：组蛋白脱乙酰基酶和DNA甲基转移酶双重抑制可有效治疗外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e38203e015a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372678, encodeId=329013e2678ec, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=ATG-010（selinexor）完成首例复发难治性外周T和NK/T细胞淋巴瘤患者给药, objectType=article, longId=200687, objectId=397520068ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397520068ed0, replyNumber=0, likeNumber=112, createdTime=2020-09-16, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397520068ed0, moduleTitle=ATG-010（selinexor）完成首例复发难治性外周T和NK/T细胞淋巴瘤患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397520068ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372677, encodeId=2be613e267739, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Blood：Avelumab治疗复发性/难治性结外NK/T细胞淋巴瘤, objectType=article, longId=199475, objectId=ce771994e50b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce771994e50b, replyNumber=0, likeNumber=124, createdTime=2020-08-16, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce771994e50b, moduleTitle=Blood：Avelumab治疗复发性/难治性结外NK/T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce771994e50b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372676, encodeId=862213e2676d1, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=外周T细胞淋巴瘤治疗——晚期难治挑战尚存，各方新药疗效可期, objectType=article, longId=198316, objectId=e83e198316b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e83e198316b3, replyNumber=0, likeNumber=97, createdTime=2020-07-31, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e83e198316b3, moduleTitle=外周T细胞淋巴瘤治疗——晚期难治挑战尚存，各方新药疗效可期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e83e198316b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372675, encodeId=bca113e26756f, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=miR-155抑制剂治疗T细胞淋巴瘤，获得美国FDA的孤儿药物指定, objectType=article, longId=197998, objectId=2dca19e99888, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dca19e99888, replyNumber=0, likeNumber=91, createdTime=2020-07-26, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dca19e99888, moduleTitle=miR-155抑制剂治疗T细胞淋巴瘤，获得美国FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dca19e99888)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372674, encodeId=6cde13e2674bf, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=多细胞因子抑制剂BNZ-1治疗皮肤T细胞淋巴瘤：安全性和有效性良好, objectType=article, longId=197837, objectId=879319e8373b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=879319e8373b, replyNumber=0, likeNumber=92, createdTime=2020-07-22, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=879319e8373b, moduleTitle=多细胞因子抑制剂BNZ-1治疗皮肤T细胞淋巴瘤：安全性和有效性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=879319e8373b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372673, encodeId=2ae513e2673bd, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Bood：结外自然杀伤/T细胞淋巴瘤患者CNS复发的预测和预防, objectType=article, longId=196933, objectId=99aa19693328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99aa19693328, replyNumber=0, likeNumber=96, createdTime=2020-07-04, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99aa19693328, moduleTitle=Bood：结外自然杀伤/T细胞淋巴瘤患者CNS复发的预测和预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99aa19693328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372672, encodeId=10a013e267211, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Blood：晚期皮肤T细胞淋巴瘤STAT-6调控基因的全基因转录组分析, objectType=article, longId=194670, objectId=14c31946e072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14c31946e072, replyNumber=0, likeNumber=96, createdTime=2020-05-25, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14c31946e072, moduleTitle=Blood：晚期皮肤T细胞淋巴瘤STAT-6调控基因的全基因转录组分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14c31946e072)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372671, encodeId=faa613e267117, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=细胞接合剂AFM13治疗T细胞淋巴瘤：已获FDA孤儿药认定, objectType=article, longId=191251, objectId=1c771912519e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c771912519e, replyNumber=0, likeNumber=103, createdTime=2020-04-04, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c771912519e, moduleTitle=细胞接合剂AFM13治疗T细胞淋巴瘤：已获FDA孤儿药认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c771912519e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372670, encodeId=fefb13e2670d9, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Lancet Haematol：过去十年，结外自然杀伤T细胞淋巴瘤的治疗进展, objectType=article, longId=189131, objectId=df8e18913157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df8e18913157, replyNumber=0, likeNumber=88, createdTime=2020-03-03, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df8e18913157, moduleTitle=Lancet Haematol：过去十年，结外自然杀伤T细胞淋巴瘤的治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df8e18913157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372669, encodeId=0b3713e26694c, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=NEJM：结外自然杀伤T细胞淋巴瘤-病例报道, objectType=article, longId=187577, objectId=0bc218e577de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bc218e577de, replyNumber=0, likeNumber=104, createdTime=2020-02-08, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bc218e577de, moduleTitle=NEJM：结外自然杀伤T细胞淋巴瘤-病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bc218e577de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372668, encodeId=052413e2668a8, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=NCCN临床实践指南：T细胞淋巴瘤（2020.V1）, objectType=article, longId=186761, objectId=1e1b186e61f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e1b186e61f0, replyNumber=0, likeNumber=82, createdTime=2020-01-27, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e1b186e61f0, moduleTitle=NCCN临床实践指南：T细胞淋巴瘤（2020.V1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e1b186e61f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

T细胞淋巴瘤

2020-05-29

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Front Oncol：西达本胺（chidamide）治疗中国复发或难治性(R/R) 外周T细胞淋巴瘤（PTCL）的真实世界的疗效

2021-11-09

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Blood：结外自然杀伤/T细胞淋巴瘤的新预后预测评分系统！

2021-08-28

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

科普贴：外周T细胞淋巴瘤（PTCL）

2021-08-08

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Blood：血管免疫母细胞性T细胞淋巴瘤的预后和预后因素

2021-08-03

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性

2021-07-14

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

协和麒麟mogamulizumab单抗在中国递交上市申请，用于皮肤T细胞淋巴瘤

2021-07-06

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Solasia宣布在日本提交抗癌药物DARINAPARSIN用于外周T细胞淋巴瘤的新药申请

2021-07-04

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

2020 CCO | 张清媛教授：外周T细胞淋巴瘤的治疗进展

2020-11-28

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Blood：组蛋白脱乙酰基酶和DNA甲基转移酶双重抑制可有效治疗外周T细胞淋巴瘤

2020-11-26

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

ATG-010（selinexor）完成首例复发难治性外周T和NK/T细胞淋巴瘤患者给药

2020-09-16

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Blood：Avelumab治疗复发性/难治性结外NK/T细胞淋巴瘤

2020-08-16

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

外周T细胞淋巴瘤治疗——晚期难治挑战尚存，各方新药疗效可期

2020-07-31

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

miR-155抑制剂治疗T细胞淋巴瘤，获得美国FDA的孤儿药物指定

2020-07-26

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

多细胞因子抑制剂BNZ-1治疗皮肤T细胞淋巴瘤：安全性和有效性良好

2020-07-22

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Bood：结外自然杀伤/T细胞淋巴瘤患者CNS复发的预测和预防

2020-07-04

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Blood：晚期皮肤T细胞淋巴瘤STAT-6调控基因的全基因转录组分析

2020-05-25

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

细胞接合剂AFM13治疗T细胞淋巴瘤：已获FDA孤儿药认定

2020-04-04

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Lancet Haematol：过去十年，结外自然杀伤T细胞淋巴瘤的治疗进展

2020-03-03

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

NEJM：结外自然杀伤T细胞淋巴瘤-病例报道

2020-02-08

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

NCCN临床实践指南：T细胞淋巴瘤（2020.V1）

2020-01-27

科室
- - 订阅+
  - 更多科室
工具
服务